The US Patent and Trademark Office (USPTO) has awarded US Patent No 8,883,728, “Intranasal administration of active agents to the central nervous system,” to Aegis Therapeutics, the company said.
The patent covers, “Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents.
Aegis markets its Intervail techology for intranasal delivery of small molecule, protein, and peptide drugs to the brain and CNS using aqueous formulations and standard nasal spray devices.
Read the Aegis Therapeutics press release.
